TRINETRA › Sectors › Healthcare
Torrent Pharmaceuticals Limited (TORNTPHARM) — share price, P/E and fundamentals
Torrent Pharmaceuticals Limited (NSE: TORNTPHARM) closed at ₹4,613.40 on 30 Oct 2026, +28.7% over one year, against a 52-week range of ₹3,532.60 – ₹5,250.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 23 Oct 2026) it reported revenue of ₹4,979 cr and net profit of ₹534 cr, a 10.7% net margin; revenue grew 50.8% and profit fell 6.8% year on year.
On four consecutive filed quarters its trailing P/E is 82.5; since 20 May 2025 its own P/E has ranged from 55.4 to 81.8 (median 66.0), and today's reading is higher than 88% of those 358 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 11.6%, ROCE 11.3%, debt-to-equity 0.76, Piotroski F-score 3 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 29% of 63 sector peers; PBT margin higher than 32% of 63 sector peers; ROE higher than 36% of 63 sector peers.
Key figures
| Last close | ₹4,613.40 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -6.4% / +12.1% / +28.7% |
| 52-week low – high | ₹3,532.60 – ₹5,250.00 |
| Market capitalisation | ₹1,75,309 cr |
| Trailing P/E | 82.5 |
| Price / book | 9.54 |
| EV / EBITDA | 33.5 |
| Earnings yield | 1.2% |
| TTM EPS | ₹55.89 |
| TTM net profit | ₹2,124 cr |
| Quarter revenue | ₹4,979 cr |
| Quarter net profit | ₹534 cr |
| Net margin | 10.7% |
| Revenue growth (YoY) | +50.8% |
| Profit growth (YoY) | -6.8% |
| Return on equity | 11.6% |
| ROCE | 11.3% |
| Debt / equity | 0.76 |
| Current ratio | 1.32 |
| Free cash flow | ₹2,063 cr |
| Piotroski F-score | 3 / 9 |
| Average daily turnover (50 days) | ₹144.2 cr |
Against Healthcare peers
| Metric | TORNTPHARM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 10.73 | 12.89 | 29 |
| PBT margin | 14.80 | 17.68 | 32 |
| ROE | 11.63 | 13.87 | 37 |
| ROCE | 11.32 | 17.26 | 19 |
| Debt / equity | 0.76 | 0.11 | 97 |
| FCF margin | 20.84 | -0.87 | 93 |
| Cash conversion | 2.23 | 1.25 | 89 |
| Trailing P/E | 82.54 | 43.07 | 85 |
Questions
What is the P/E ratio of Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited's trailing P/E is 82.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 20 May 2025 its P/E has ranged 55.4–81.8.
What were Torrent Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Torrent Pharmaceuticals Limited reported revenue of ₹4,979 cr and net profit of ₹534 cr (consolidated), filed with the exchange on 23 Oct 2026.
What is Torrent Pharmaceuticals Limited's ROE?
Return on equity is 11.6% based on the balance sheet dated 30 Sept 2026.
Does Torrent Pharmaceuticals Limited have debt?
Debt-to-equity is 0.76 on the balance sheet dated 30 Sept 2026.
What is TORNTPHARM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, TORNTPHARM traded between ₹3,532.60 and ₹5,250.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.